Metabolic dysfunction-associated steatotic liver disease (MASLD), previously called non-alcoholic fatty liver disease, is a ...

Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.

This article explores compensated cirrhosis in more detail, including its causes, diagnosis, and treatment. It also answers some common questions about the condition. Healthcare professionals ...

Cryptogenic cirrhosis is liver scarring that occurs without a known cause. It can cause fatigue, appetite loss, weight loss, swelling, and jaundice and may lead to irreversible liver damage.

The North America liver disease treatment market accounted for $6,970 million in 2019, and is expected to reach $8,318 million by 2027, registering a CAGR of 5.2% from 2020 to 2027. Furthermore, liver ...

Cardiometabolic MASH: Emphasize aggressive management of metabolic and cardiovascular risks alongside liver disease treatment. "This research marks a turning point," says Prof. François Pattou.